Y0001173
Filgrastim
European Pharmacopoeia (EP) Reference Standard
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Qualité
pharmaceutical primary standard
Famille d'API
filgrastim
Fabricant/nom de marque
EDQM
Application(s)
pharmaceutical (small molecule)
Format
neat
Température de stockage
−70°C
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
Description générale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Filgrastim EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Conditionnement
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Autres remarques
Sales restrictions may apply.
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Choose from one of the most recent versions:
Certificats d'analyse (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Ashton E Beggs et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 69(24), 2147-2148 (2012-12-12)
A case of leukopenia in a patient receiving colchicine for calcium pyrophosphate dihydrate deposition disease, or pseudogout, is reported. An 85-year-old man experienced leukopenia likely due to colchicine. His medical history included chronic lymphocytic leukemia (CLL), pseudogout, osteoarthritis, and hypertension.
Kirsi-Maija Kaukonen et al.
BMC infectious diseases, 13, 51-51 (2013-02-01)
Heparin Binding Protein (HBP) is released to blood circulation from activated neutrophils in bacterial infections. It is a potential inducer of vascular leakage and precludes the development of septic shock. Filgrastim induces the production of new neutrophils and modulates their
Effect of granulocyte colony-stimulating factor on circulating immune and stem cells in septic shock: revisit the basics and consider giving it another chance.
Tomasz Skirecki et al.
American journal of respiratory and critical care medicine, 187(2), 217-219 (2013-01-17)
L M Rozhdestvenskiĭ et al.
Radiatsionnaia biologiia, radioecologiia, 52(5), 503-509 (2012-12-12)
In the experiments on F1 (CBA x C57BL) and BALB mice irradiated by 137Cs gamma-rays, preparations of unglycosilated G-SCF such as Neupogen and their domestic analogs Leucostim and Neupomax were investigated. The tests such as 9-day bone marrow cellularity (BMC)
C Kelaidi et al.
Annals of hematology, 92(5), 621-631 (2013-01-30)
Darbepoetin (DAR), with or without granulocyte colony-stimulating factor (G-CSF), has proved effective in treating anemia in patients with lower-risk myelodysplastic syndrome (MDS), but its effects on quality of life (QoL) and exercise functioning are less well established. In this phase
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique